MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer

Background: Immune checkpoint inhibitors have changed the treatment landscape for advanced non-small cell lung cancer. However, only a small proportion of patients experience clinical benefit from ICIs. Thus, the discovery of predictive biomarkers is urgently warranted. Evidence have shown that gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Lei, Li, Man, Deng, Ling, Niu, Yuchun, Tang, Yichun, Wang, Yu, Guo, Linlang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076956/
https://www.ncbi.nlm.nih.gov/pubmed/33927616
http://dx.doi.org/10.3389/fphar.2021.625593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076956/
https://www.ncbi.nlm.nih.gov/pubmed/33927616
http://dx.doi.org/10.3389/fphar.2021.625593

Ejemplares similares